azacitidine
There was no significant difference between patients treated with azacitidine on a five-day or a five-plus-two-day schedule..
Alexandre Bazinet, MD, and colleagues conducted the single-center, dose-expansion phase I/II trial...
It led to an overall response rate of 74% in patients with newly diagnosed IDH2-mutated myelodysplastic syndrome.
Advertisement
The results of the trial were presented during the 2022 ESMO Congress by Chunkang Chang, MD, PhD.
The researchers analyzed data from previously untreated adult patients with low- or intermediate-risk MDS.
The analysis results have clinical implications, as venetoclax-based regimens are the standard of care for patients.
Advertisement
Investigators retrospectively identified patients with PTCL who were treated with romidepsin plus subcutaneous azacitidine.
A retrospective study showed that response rate and survival outcome are still modest for high-risk patients.
The study analyzed 70 transplant-ineligible patients with high-risk MDS and MDS/AML with less than 30% of myeloblasts.
The approval was based on data from a trial that randomized patients with newly-diagnosed IDH1-mutated AML.
The FDA approval was based on data from the AZA-JMML trial, which observed half of patients reach confirmed responses.
Event-free survival was longer in patients treated with ivosidenib plus azacitidine compared with placebo plus azacitidine.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.